What is actually in there

Vinpocetine: A Drug Sold As A Supplement

Most ingredients on a supplement label are plants, or parts of plants, or things extracted from plants. Vinpocetine is none of those. It is a molecule made in a laboratory, prescribed as a medicine in several countries, and sold over the counter in the United States under the same labelling rules as a herbal tea.

By Primal Grow Pro Team · Last updated September 19, 2026 · 9 min read · What is actually in there

What it actually is

Vincamine is an alkaloid found in the lesser periwinkle. Vinpocetine is not vincamine. It is a chemical modification of it, made in a laboratory, developed in Hungary in the nineteen-seventies and marketed there and elsewhere as a medicine for cerebrovascular conditions.

That history matters because it explains the shape of everything that follows. A compound developed as a pharmaceutical has pharmaceutical-style research behind it: defined daily amounts, pharmacokinetic studies, clinical endpoints. It also has a pharmaceutical’s risk profile, and it arrived in the American supplement aisle without the labelling that normally accompanies one.

Five rows, and the first is the one that changes everything downstream. A synthesised molecule sold under supplement labelling rules is a specific kind of thing.

The practical upshot of that table is a single sentence. When you read vinpocetine on an ingredient list, you are reading the name of a drug that is being sold to you under food rules, and the questions worth asking about it are drug questions rather than botanical ones.

What the evidence amounts to

The Cochrane review of vinpocetine for cognitive impairment and dementia is the definitive assessment, and it is short on material. Three trials met its inclusion criteria. All three predate the 1990s. They used 30 and 60 milligrams a day.

The review concluded that the evidence was inconclusive, and it noted that vinpocetine has never been approved by any regulator for cognitive indications despite being available as a medicine in several countries.

That is an unusual position for an ingredient to be in: enough of a drug to be prescribed somewhere, not enough of an evidence base to have been approved for the thing it is prescribed for. Reading the two facts together is the fairest summary anyone can give.

Why three old trials is a specific kind of problem

Trials from before the 1990s were conducted to different standards of randomisation, blinding, reporting and statistical analysis. That is not a slur on the researchers; it is a description of how methodology has changed.

It also means the gap has never been filled. An ingredient with three inconclusive old trials and no modern replication is not an ingredient that has been tested and failed. It is one that has largely not been tested, which is a different and in some ways less satisfying position.

The finding that decides where the bottle lives

The National Toxicology Program ran embryo-fetal development studies in rats and rabbits. The results were dose-dependent: post-implantation loss, reduced fetal weight, and ventricular septum defects in rats at 60 milligrams per kilogram.

The detail that gives the finding its weight is that these effects appeared without maternal toxicity. An effect that only shows up at amounts that also make the mother ill is a different and less worrying kind of finding. This one was not that.

The authors’ conclusion names a potential hazard for pregnant women. Animal studies do not translate directly to humans and nobody should read them as though they did, but a developmental finding of this shape is exactly the kind that regulators and researchers take seriously.

The practical consequence is narrow and easy to act on: keep a bottle containing this ingredient out of a cupboard anyone who could become pregnant might reach into, and keep it labelled.

What is actually in the bottles that claim it

This is the section that is less about vinpocetine and more about the aisle it is sold in, and it is the most quietly damning piece of research cited anywhere on this website.

Drawn from Avula and colleagues, 2016. It is an analysis of an industry rather than of any single product.

Seventeen of twenty-three contained the ingredient. Among those, the quantity per daily serving ranged from three tenths of a milligram to thirty-two milligrams, which is a spread of more than a hundredfold between products sold on the same shelf under the same ingredient name.

Six contained none at all.

It is worth being precise about what that shows and what it does not. It does not show that any particular product on sale today is mislabelled. It shows that, at the time of the analysis, a printed ingredient name on an American supplement was an unreliable guide to what was in the capsule, and that the quantity behind such a name varied by two orders of magnitude.

That is the strongest available argument for treating a printed number as a declaration made at manufacture rather than as a measurement, and it is the reason the wider literature on supplement adulteration is worth reading once by anybody buying regularly in this aisle.

The origin question, and one seller who answers it

Three of the twenty-three products in that analysis implied their vinpocetine came from lesser periwinkle. It does not, in the sense those labels implied: the compound is synthesised from vincamine rather than extracted as such from a plant.

The seller of the product on this website attributes its vinpocetine to Voacanga africana seeds. That is a specific claim about a source, it is more than most sellers in this aisle bother to state, and it deserves the credit that specificity earns. It is also a claim nobody outside the manufacturer can verify, which is true of almost every sourcing claim in this category.

What the seller does not state is how much. No quantity appears for vinpocetine or for any of the other six names, which is covered in full on the ingredients page.

What this says about the category

Three lessons generalise beyond this one ingredient, and they are the reason this article exists on a website that sells a product containing it.

The first is that “natural” is not a property that can be read off an ingredient list. A formula can carry a natural-ingredients mark and contain a molecule synthesised in a factory, because the word has no settled definition in supplement labelling. That is a fact about the labelling system rather than about any seller.

The second is that regulatory status is geographic. An ingredient can be a prescription medicine in one country and an over-the-counter supplement in another, and a competitor subject to anti-doping rules should clear it with their own governing body rather than assume a supplement label settles the question.

The third is that an old, thin evidence base is not the same as a negative one, and both are different from a good one. Three inconclusive trials from the 1980s is a fair description of what is known here, and any product implying more has gone beyond what the research supports.

What a reader should actually do

• Notice when it is on a list. It is not an alarming ingredient and it is one worth knowing is there, because it behaves differently from everything around it.
• Keep the bottle away from anyone who could become pregnant. This is the one concrete action the animal data supports, and it costs nothing.
• Check it against any governing body rules if you compete. Regulatory status varies by country and a supplement label is not a compliance document.
• Ask the seller for the quantity, in writing. On a label with no numbers this is one of the four questions worth putting to an order desk before a large order.
• Read the rest of the list with the same attention. The NCCIH's general guidance on using supplements sensibly is five minutes well spent before any first purchase in this aisle.

None of that adds up to avoiding products that contain it. It adds up to knowing what it is, which is the distinction this entire article has been circling: an ingredient that behaves like a drug is not necessarily a problem, and it is always worth recognising.

References